Key Points - The company announced a cash dividend of 0.40 CNY per share for A shares [1][2] - The dividend distribution was approved at the annual shareholders' meeting on May 29, 2025 [1] - The total cash dividend to be distributed amounts to approximately 484.97 million CNY based on the total share capital of 1,212,416,854 shares [1][2] Relevant Dates - The record date for the dividend is June 17, 2025, with the ex-dividend date on June 18, 2025, and the payment date also on June 18, 2025 [2][3] Distribution Implementation - Cash dividends will be distributed through China Securities Depository and Clearing Corporation Limited, Shanghai Branch, to shareholders registered by the record date [2] - The distribution does not involve the issuance of bonus shares or capital increase [2] Taxation Information - For individual shareholders holding shares for over one year, the cash dividend is exempt from personal income tax, resulting in a net distribution of 0.40 CNY per share [3][4] - For shares held for less than one year, the tax rate varies based on the holding period, with a maximum effective tax rate of 20% for shares held for one month or less [3][4] - For Hong Kong investors, the net cash dividend after a 10% withholding tax will be 0.36 CNY per share [4]

Group 1 - The company held its fourth meeting of the fourth Supervisory Board, which was convened by the chairperson Meng Peng, with all three supervisors present, complying with relevant laws and regulations [1] - The Supervisory Board approved the proposal to conclude certain fundraising projects and permanently supplement working capital with the remaining funds, which is seen as a reasonable decision to enhance the efficiency of fund usage and beneficial for the company's long-term development [1][2] - The proposal regarding the cancellation of unvested restricted stock due to the departure of two incentive targets and the failure to meet performance targets for the 2024 fiscal year was discussed, resulting in a total of 1.63205 million shares being rendered invalid [2][3] Group 2 - The voting results for the proposal to conclude fundraising projects showed unanimous support with 3 votes in favor, while the proposal regarding the cancellation of restricted stock could not be resolved due to insufficient non-related supervisors present to form a quorum [2][3] - The company plans to disclose further details regarding the cancellation of restricted stock on the official information platform [2][3]

Group 1 - The annual shareholders' meeting of Yifeng Pharmacy Chain Co., Ltd. was held on May 29, 2025, in Changsha, Hunan Province [2] - The meeting was conducted in compliance with the Company Law and the company's articles of association, utilizing both on-site and online voting methods [2][3] - All current directors and supervisors attended the meeting, with a total of 9 directors and 3 supervisors present [3] Group 2 - All proposed resolutions were approved during the meeting, including the annual work reports of the board and supervisory committee, financial statements, and profit distribution plan for 2024 [4][5][6] - The meeting authorized the board to formulate a mid-term dividend plan and approved the appointment of an accounting firm for 2025 [5][6] - A significant resolution regarding the company's shareholder return plan for the next three years (2025-2027) was also passed [6] Group 3 - The meeting was witnessed by lawyers from Hunan Qiyuan Law Firm, confirming that the meeting's procedures and voting results were legally valid [6]

Core Viewpoint - The company, Yifeng Pharmacy Chain Co., Ltd., is set to hold an annual performance briefing for 2024 and the first quarter of 2025 on June 3, 2025, to provide insights into its operational results and financial status [2][3][4]. Group 1: Performance Briefing Details - The performance briefing will take place on June 3, 2025, from 15:00 to 16:00 [4]. - The event will be held at the Shanghai Stock Exchange Roadshow Center and will utilize video and online interaction for communication [4][5]. - Investors can submit questions for the briefing from May 27 to June 2, 2025, through the Roadshow Center website or via the company's email [2][5]. Group 2: Management Participation - Key participants in the briefing will include the Chairman and CEO, Mr. Gao Yi, the Financial Officer, Mr. Wang Yonghui, the Board Secretary, Mr. Fan Wei, and the Independent Director, Mr. Huang Chunan [4]. Group 3: Shareholding and Reduction Plan - Prior to the reduction plan, the Executive President, Mr. Gao Youcheng, held 201,600 shares, representing 0.0166% of the total share capital, while the Assistant President, Mr. Yan Jun, held 99,600 shares, representing 0.0082% [8]. - The reduction plan was disclosed on January 24, 2025, with a maximum reduction of 75,300 shares planned, which was successfully executed within the specified timeframe [9][10].

Core Viewpoint - The company is utilizing idle raised funds for entrusted financial management to enhance fund efficiency and increase returns while ensuring that the original purpose of the raised funds remains unchanged [3][13]. Group 1: Entrusted Financial Management Details - The amount for entrusted financial management is 212 million yuan [4]. - The source of the funds is idle raised funds [5]. - The company has received approval from the China Securities Regulatory Commission for issuing convertible bonds totaling 1.797 billion yuan, with a net amount of approximately 1.780 billion yuan after deducting issuance costs [6]. Group 2: Approval and Procedures - The board of directors approved the proposal for using idle raised funds for entrusted financial management during the 15th meeting of the 5th board on April 15, 2025, allowing a maximum of 300 million yuan for this purpose [8]. - The investment products will be selected based on high safety and liquidity, with a validity period of 12 months for the approved amount [8]. Group 3: Risk Management and Control Measures - The company will conduct strict evaluations of investment products, focusing on low-risk financial products, while acknowledging potential market volatility risks [9][10]. - Measures include maintaining an investment ledger, regular audits by the audit department, and oversight by independent directors and supervisors [10][11]. Group 4: Impact on the Company - The investment in short-term financial products will not affect the normal operation of the company's main business or its daily cash flow needs [13]. - This strategy aims to generate additional investment returns, enhancing the company's performance and providing better returns for shareholders [13].

证券代码：603883 证券简称：老百姓 公告编号：2025-007 老百姓大药房连锁股份有限公司 第五届董事会第八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 老百姓大药房连锁股份有限公司（以下简称"公司"）于2025年4月3日发出召开第五届董事会第八次会议 的通知，会议于2025年4月11日在公司会议室以通讯方式召开，本次董事会应参加表决的董事9名，实际 参加表决的董事9名。本次会议由董事长谢子龙先生主持，董事会秘书等相关人员列席会议。 二、董事会会议审议情况 （一）审议通过《关于公司高管离任的议案》 本议案已经公司第五届董事会提名、薪酬与考核委员会第四次会议审议通过。 为深化组织改革，经公司与江宇飞先生友好协商，江宇飞先生不再担任公司副总裁职务，离任后将不再 担任公司任何职务。 表决结果：同意9票，反对0票，弃权0票，表决通过。 具体内容详见公司在上海证券交易所网站（http://www.sse.com.cn）同日披露的《关于公司高管离任的 公告》。 特此公告。 老百姓大药房连锁 ...

公司于2025年4月1日获悉公司控股股东医药集团所持有公司的部分股份已办理解除质押，现将相关情况 公告如下： 一、本次股份解除质押的具体情况 2023年医药集团将其持有的7,600,000股股票质押给中银国际证券股份有限公司，具体内容详见公司于 2023年6月2日在上海证券交易所网站（www.sse.com.cn）披露的《关于控股股东股份质押的公告》（公 告编号：2023-026）。 证券代码：603883 证券简称：老百姓 公告编号：2025-006 老百姓大药房连锁股份有限公司关于控股股东部分股份解除质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ●截至本公告日，老百姓大药房连锁股份有限公司（以下简称"公司"）控股股东老百姓医药集团有限公 司（以下简称"医药集团"）持有公司股份198,564,175股，占公司股份总数的26.12%，本次解除股份质押 10,680,000股后，医药集团持有公司股份累计质押数量为138,324,000股，占其持股总数的69.66%，占公 司总股本的18.20%。控股 ...

公司于 2025 年 4 月 1 日获悉公司控股股东医药集团所持有公司的部分股份已办理 解除质押，现将相关情况公告如下： 证券代码：603883 证券简称：老百姓 公告编号：2025-006 老百姓大药房连锁股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重要内容提示： ●截至本公告日，老百姓大药房连锁股份有限公司（以下简称"公司"）控股股 东老百姓医药集团有限公司（以下简称"医药集团"）持有公司股份 198,564,175 股， 占公司股份总数的 26.12%，本次解除股份质押 10,680,000 股后，医药集团持有公司股 份累计质押数量为 138,324,000 股，占其持股总数的 69.66%，占公司总股本的 18.20%。 控股股东及一致行动人（医药集团与陈秀兰）合计持有公司股份数量为 212,129,873 股，占公司总股本比例为 27.91%，累计质押股份数量为 138,324,000 股，占其所持股 份比例为 65.21%，占公司总股本比例为 18.20%。 一、本次股份解除质押的具体情况 司， ...